news
British pharma responds to UK’s Chancellor’s new Spending Review
The ABPI has commented on the new Spending Review and outlined ways the UK government can help the life sciences sector.
List view / Grid view
National Health Service (NHS)
news
NICE rules nivolumab is not cost effective for use on NHS
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
news
NICE recommends Liraglutide for treatment of obesity and non-diabetic hyperglycaemia
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
article
Should life sciences businesses require employees to use the NHS COVID-19 App when at work?
The NHS COVID-19 App was introduced in the UK on 24 September. Many welcome its arrival as another step to contain the spread of COVID-19, while others are concerned about using the app for data and privacy reasons. In this article Helen Farr, a partner at Taylor Wessing, explores the…
article
Biosimilars: the future of competition
Earlier this year, the British Biosimilars Association (BBA), the trade body representing the interests of biosimilar manufacturers, welcomed Dr Andrew Ellis as its new Chair. In this interview, Nikki Withers asks why biosimilars are so important for pharma and how he foresees the market evolving in the coming years.
article
The importance of continually evolving solid dosage forms
Solid dosage forms have been one of the foremost choices of drug administration for generations. However, with an ever-growing global population, evolving customer demands and continual updates to regulations comes greater need for advanced medicines and progress in this sector. This article explores the benefits and how the field must…
article
COVID-19: the great ventilator challenge
Many COVID-19 patients who are admitted to intensive care in the UK, and globally, require mechanical ventilation. However, our healthcare systems are not prepared for the vast numbers of patients requiring this form of treatment. In this article, Adrian Toutoungi expounds how government and industry is working to push production…
news
Francis Crick Institute and collaborators to offer COVID-19 testing for key workers
The institute has paused cancer research and repurposed its laboratories and scientists to provide a rapid COVID-19 testing facility for NHS staff and other key workers.
news
How to take care of your mental health during the COVID-19 pandemic
During the COVID-19 pandemic, when many are in lockdown or self-isolating, mental health could suffer. This article suggests some ways to stay healthy over this period.
news
UK bans parallel exporting of crucial medicines to help COVID-19 patients
The UK government has announced that the parallel export of certain essential medicines is banned, to preserve drugs for the treatment of coronavirus patients.
news
NICE fails to recommend pembrolizumab in final draft guidance
The UK NICE has not found pembrolizumab cost-effective for use on the NHS, after a review of evidence collected while the drug was available via the Cancer Drugs Fund.
news
Medicines and Medical Devices Bill introduced in UK
A new bill is now effective in the UK which aims to improve regulation for medical devices and ensure patient safety, as well as allow hospitals to develop personalised medicines.
news
Dr William van’t Hoff next NIHR Clinical Research Network Chief Executive
The next Chief Executive of the National Institute for Health Research’s Clinical Research Network has been announced as Dr William van’t Hoff.
news
NICE does not recommend esketamine for treatment-resistant depression
Esketamine nasal spray did not receive a positive opinion from NICE due to inadequate comparisons to other therapies and concerns over its cost effectiveness.
article
Five of the most recent pharma collaborations in 2020
As companies continue to collaborate and share their expertise to develop therapeutics targeting a wide range of diseases, European Pharmaceutical Review explores the aims of the most recent partnerships.
